#United States #Washington #financial results #Danaher Corporation #DHR

Danaher Corporation Reports Fourth Quarter and Full Year 2024 Results

Danaher Corporation, a leading innovator in life sciences and diagnostics, has shared its financial results for the fourth quarter and full year of 2024, indicating robust performance across its operations. The reported net earnings for the fourth quarter reached an impressive $1.1 billion, equating to $1.49 per diluted share. Moreover, the non-GAAP adjusted diluted earnings were reported at $2.14 per share. Year-over-year, revenues climbed by 2.0% to $6.5 billion, with core revenue showing a modest increase of 1.0%.

The full year results highlight total net earnings of $3.9 billion, resulting in $5.29 per diluted share, while adjusted diluted earnings per share stood at $7.48. Total revenues for the year amounted to $23.9 billion, remaining flat compared to the previous year, with non-GAAP core revenue reflecting a slight decline of 1.5%. Operating cash flow for the year was notably strong at $6.7 billion, translating to a free cash flow of $5.3 billion, thus reaffirming Danaher's strong financial health.

Key Highlights from Q4 2024:

• - Net Earnings: $1.1 billion ($1.49/share)
• - Revenue: $6.5 billion
• - Operating Cash Flow: $2.0 billion
• - Free Cash Flow: $1.5 billion

Full Year 2024 Insights:

• - Net Earnings: $3.9 billion ($5.29/share)
• - Total Revenue: $23.9 billion
• - Operating Cash Flow: $6.7 billion
• - Free Cash Flow: $5.3 billion

Rainer M. Blair, President and CEO of Danaher, emphasized, "We concluded the year on a strong note, with our core revenue exceeding expectations across all segments. The team's execution also resulted in improved cash flow and margin expansion. Looking towards the future, we are more strategically positioned than ever in our 40-year history, as our portfolio transformation establishes us as a focused innovator in life sciences and diagnostics, primed for sustained growth."

Looking ahead, Danaher provided guidance for the first quarter of 2025, projecting a low-single-digit decline in non-GAAP core revenue year-over-year. However, for the full year, the company expects core revenue to increase by approximately 3%, suggesting an optimistic outlook for recovery and growth.

Danaher also hosted an investor conference call to discuss these results and financial guidance in further detail. Participants were encouraged to visit the ‘Investors’ section of the company’s website for additional resources and a replay of the call.

The remarkable performance of Danaher can be attributed to its commitment to innovation and scientific excellence, evident in its wide-reaching capabilities, which aim to tackle the critical health challenges affecting patients globally. With a dedicated workforce of about 63,000 associates, Danaher is not just focused on improving the quality of life today but also on laying the groundwork for a sustainable future.

For more detailed information regarding the full financial statements and a breakdown of non-GAAP financial measures, stakeholders can access the supplemental materials available on Danaher’s official website.

In conclusion, Danaher’s robust financial standing and strategic positioning underscore its potential for continued growth and success in the life sciences and diagnostics sectors, as it prepares to meet the challenges and opportunities of the coming years.